The efficacy and safety of relatlimab/nivolumab combination therapy in patients with advanced melanoma: a systematic review.

Abstract

Finding a treatment approach with high efficacy and minimal adverse reactions for advanced melanoma is still challenging. This study aimed to review and summarize available evidence regarding the effectiveness of the newly FDA-approved combination therapy of Relatmlimab and Nivolumab in patients with advanced melanoma and its comorbidities. We searched MEDLINE, EMBASE, and Cochrane Library for studies published in any language till 29/11/2023. We used the following Mesh and Emtree words, "melanoma" AND "relatlimab" AND "nivolumab". We screened 398 articles and included two single-arm clinical trials (N = 2) and one randomized clinical trial (RCT) (N = 1). In conclusion, The relatlimab/nivolumab combination therapy showed promising results for advanced melanoma patients. However, further research and longer follow-up periods are needed to compare it with previous treatments and validate its long-term effectiveness and safety.